Please login to the form below
Cancer Drugs Fund
This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
NICE recommended Darzalex in March this year via the Cancer Drugs Fund (CDF) for use as a monotherapy in relapsed and refractory myeloma in patients who have had three previous treatments. ... Pfizer responded by saying that the list prices of just 10%
Latest news
-
Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach
NICE says that because neither data collection from clinical practice or the ongoing trials would resolve the identified uncertainty, Opdivo was not suitable for use within the Cancer Drugs Fund for ... It is already approved for patients with ALK
-
Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund
Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund. ... This means it will now be removed from the ‘managed access’Cancer Drugs Fund (CDF) the first drug to achieve this since the remodelled system was launched two years
-
NICE backs Tesaro’s Zejula via the CDF
NICE backs Tesaro’ s Zejula via the CDF. Recommends the drug for second-line use in ovarian cancer patients. ... The drug, which was the first oral medicine licensed in Europe for use in women with and without a BRCA mutation, is available via the
-
Keytruda gains NICE clearance in first line bladder cancer
Keytruda gains NICE clearance in first line bladder cancer. MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance. ... Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s
-
NHS seeks 'solution creators' from within pharma
There has also been “a degree of convergence”among the people and bodies that work on assessing new medicines, he added, whether they be involved with NICE, the Cancer Drugs Fund
More from news
Approximately 48 fully matching, plus 104 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare
A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... pharma’to become chief executive of Redx, a promising
-
Uncertainty, austerity and Brexit
Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run
-
Opening up market access
In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.
-
Opening up market access
In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.
-
Stepping up to payer-driven market access
products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.
More from intelligence
Approximately 2 fully matching, plus 14 partially matching documents found.
Latest appointments
-
New health ministers and re-appointments after reshuffle
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the
-
Celgene names general manager for UK and Ireland
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
How to make the most of online communities
topical healthcare issues including NICE, the Cancer Drugs Fund, biosimilars, the impact of Digital on pharma and the NHS in general.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
PMHub
StratX
StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
